Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immunotherapy drug shows promise in stopping rare skin cancer's return

NCT ID NCT03271372

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times

Summary

This phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer had spread to lymph nodes and was removed by surgery or radiation. About 100 adults with stage III Merkel cell cancer will receive either avelumab or a placebo to see if the drug improves relapse-free survival. Avelumab works by helping the immune system attack cancer cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III MERKEL CELL CARCINOMA AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • University of California Irvine Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • University of Colorado Cancer Center University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of North Carolina Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599, United States

Conditions

Explore the condition pages connected to this study.